ARTICLE | Product Development
Propelled by Ionis deal, Aro raises $88M series A to advance targeted oligo pipeline
J&J spinout readying first two Centyrin-oligo conjugates for the clinic
January 6, 2021 1:30 AM UTC
A deal with antisense heavyweight Ionis attracted the investor firepower fueling Aro’s transition from platform development to product advancement.
Aro Biotherapeutics Co. raised an $88 million series A round Tuesday led by Northpond Ventures and Cowen Healthcare Investments. HealthCap, BVF Partners L.P. and Ridgeback Capital also participated, along with existing investors, Johnson & Johnson Innovation – JJDC, BioMotiv and Ionis Pharmaceuticals Inc. (NASDAQ:IONS). ...